Patent Application
20190224257
The present invention relates to reinforcing materials for angiogenesis activities, which are useful pharmaceutical compositions for angiogenesis therapy.
Western life-style and aging society of Japan yearly cause an marked increase in number of patients suffering from peripheral arterial disease (PAD), which is based on arteriosclerosis brought by risk factors such as aging, smoking, diabetes, hypertension and metabolic disorders of lipids. According to the report from American Heart Association, furthermore, popularization of noninvasive examination tests for PAD detected a contract rate of about 2-3% below age of 50 years and that of about 20% over 75 years old. And approximately about 40% PAD patients are known to show no indications.
Presently, there are, as therapeutic methods for PAD, treatments with drugs such as anti-platelets, vasodilator, and prostaglandins, or with vascular stent, and surgical bypass operation. However, effects by therapy with drugs are limited, and treatment with vascular stent or surgical bypass operation, the first choice of treatment for serious patients, are not always adopted. As PAD resistant to known therapeutic methods critical limb ischemia (CLI) is known. CLI is defined as the state accompanying chronic ischemic pain at rest and ischemic skin disorder (ulcer and gangrene). Prognosis of CLI is gloomy. At one year after the onset of CLI it is known that 25% of patients lose a leg(s) and 25% of patients are dead.
In recent clinical research various cell therapy and gene therapy as neovascular treatments of PAD. Bone marrow mononuclear cells and peripheral mononuclear cells are used for the cell therapy. Recombinant angiogenesis factors are used for the gene therapy. These factors used for the gene therapy, for example, are vascular endotherial growth factor (VEGF), fibroblast growth factor (FGF), and hepatic growth factor (HGF). These genes for angiogenesis factors enhances angiopoiesis in ischemic tissues by expressing these factors. And by the use of these factors it was possibly ascertained that development of collateral blood vessels in model animals of heart or limb ischemia is promoted and/or enhanced (Circulation 90, 11-228-11-234 (1994).
Therapy for vasculopathy with above-mentioned angiogenesis factors is designated as “angiogenesis therapy”. More recently, using gene for above-mentioned angiogenesis factors thrapeutic angiogenesis studies in ischemic and arterial diseases have been actively carried out.
Furthermore, a drug composition of angiogenesis therapy is one described in WO2002/000258. The drug composition of angiogenesis therapy mentioned in patent reference 1 is the one containing gene for HGF or VEGF and prostacyclin synthase gene as effective components.
By the way, the above-mentioned therapy using angiogenesis factors are not effective in all cases of PAD and their and long-term effectiveness and noxious events are also not known. Especially, the incident and/or growth of tumors caused by the gene therapy with growth factors can't be negligible. Therefore, developments of new therapy have been desired for solving the above-mentioned problems.
In pathologic state vascular endothelium is injured and decreases in vasodialators such as nitric oxide, prostaglandin, endothelium-derived hyperpolarization factor (EDHF) and VEGF, and increases in vasoconstrictors, angoutensin-2, endothelin-1 etc. these vascular factors are can be useful for the treatment of PAD. Actually prostanoid is used for the clinical treatment of PAD and pulmonary arterial hypertention.
Therefore, the present inventors gave attention to prostacyclin synthase (PGIS), the synthase for prostacyclin (prostaglandin I2) with activities of anti-platelet aggregation, vasodialation, and angiogenesis.
PGIS gene is a gene encoding an enzyme catalyzing the bio-synthesis of a remedy showing high effectiveness in treatment of experimental models of pulmonary hypertension and endoterium-injured arterioscrelosis. The metabite shows activities inducing anti-platelet aggregation, vasodialation, and angiogenesis. The gene therapy raises a long-term expression of the gene in local lesion, so that noxious side effects by the products always become issues. Clinical research with growth factors is possibly accompanied by occurrence and development of tumors. In the clinical cases with PGI2 drugs, however, there has been no report on tumorigenesis, and the safety of PGI2 drugs is high because of their vasodialation and vaso-protective activities Similarly, adeno-associated virus vector is judged to be the most suitable vector for the gene therapy due to the safe and active gene expression maintained for a relatively long-time.
In above-mentioned clinical research on critical limb ischemia plasmid or aveno virus are used as an expression vector. It is, however, with plasmid vectors that the strong and long gene expression is difficult to be obtained and that the frequent administration is necessary to maintain the expression level. Although a strong gene expression is obtained with the adenovirus vector, it has a short effect and the strong immunogenicity, and shows some concern about its safety. Conventionally, virus vectors have high transgenic activities, but their pathogenicities are often discussed in the human use. On the other hand AAV vectors deserve the attention because of a high efficiency and long-term expression in nondividing cells such as muscle and nerve cells, and their nonpathogenicity to human.
Thus, present inventors, using AAV as a gene transfer vector, carried out the gene transfer in skeletal muscle of human prostacyclin synthase synthesizing prostaglandin I2 (PG I2) resulting in improvement of the condition of pulmonary hypertension model mouse. In this experiment intense expression of the transferred PGIS gene was recognized in the local skeletal muscle receiving the gene transfer. It is obtained from this experiment the information that the PGIS gene transfer is hopeful in treatment of limb ischemia.
In addition, for the gene therapy not only selection of the cure gene but also a sort of the vector for gene transfer influences the efficiency of gene transfer, namely the effect of treatment.
The vector for gene therapy is expected to express long time in a possibly high level of the cure gene in the lesion. However, many plasmids or non viral vectors were in the past gene therapy studies and with these vectors strong and long-term expression on the cure gene was difficult.
Incidentally, in case of adeno-associated virus (AVV) as a virus vector it has an strong tropism for skeletal muscle cells and can achieve a strong and long-term cure gene expression. This AVV is used in the gene therapy for human hemophilia, cryptic fibrosis, Parkinson disease, and its high safety and effective is verified. By the use of AVV achieving a strong and long-term efficient gene expression, a long-term expression of the cure gene is attained and a possibility of its clinical application is expected.
Present inventors, based on the above-mentioned evidence, reached to the completion on the present invention.
The present invention is concerned with the drug composition of angiogenesis used for the treatment or prevention of peripheral arterial disease. This drug composition contains, as the active component, the adeno-associated virus (AVV) inserted with human gene for PGIS producing prostaglandin I2 which at least induces the activities of anti-platelet aggregation, vasodialation, and/or angiogenesis.
Particularly, this drug composition of angiogenesis therapy is characteristic of the recombinant adeno-associated virus (AVV) inserted with the gene for production of a factor inducing angiogenesis.
Noteworthy, the present investigation is concerned with the drug composition of angiogenesis used for the treatment or prevention of peripheral arterial disease, which contains the adeno-associated virus (AVV) inserted with human gene for PGIS producing prostaglandin I2 which at least induces the activities of anti-platelet aggregation, vasodialation, and/or angiogenesis or the recombinant adeno-associated virus (AVV) inserted with the gene for the angiogenesis factor.
Here, the use of types 1 or 2 is efficient as the adeno-associated virus (AVV).
The drug composition for angiogenesis therapy in the present invention includes a pharmaceutically permissible carrier such as the recombinant adeno-associated virus (AVV) inserted with the gene for human PGIS or human PGIS and the angiogenesis factor.
The gene coding for the angiogenesis factor used in the drug composition for angiogenesis therapy of the present invention is possibly the entire or a part of the gene coding for a protein or a peptide, which can newly induces vasculogenesis.
Especially, as the gene for angiogenesis factor, vascular endotherial growth factor (VEGF) is acceptable.
The present invention, as described previously, presents a drug composition for angiogenesis therapy useful in treatment or prevention of peripheral arterial disease, which includes human gene for PGIS (hPGIS) producing prostaglandin I2 which induces the activities of vasodialation, and/or anti-platelet aggregation, and the recombinant adeno-associated virus (AVV) inserted with the gene for the angiogenesis factor
In use of the present angiogenesis therapy, the “gene for angiogenesis” inserted in adeno-associated virus (AAV) is, similarly to the human PGIS gene, the gene coding for the entire or a part of a protein or a peptide, which newly induces vasculogenesis nad shows either activity of inhibition of platelet aggregation, vasodialation, angiogenesis. Namely listed are gene for endotherial growth factor (VEGF), VEGF-2, acidic FGF (aFGF), basic FGF (bFGF), TGF-α, TGF-β, platelet-derived endotherial growth factor (PD-ECGF), platelet-derived growth factor, tumor necrosis factor-α (TNF-α), insulin-like growth factor, angiopoieti-1 etc. Aditionally candidates are the gene for HIF-1 and ets family translation factors including ets-1 which regulate the gene expression of VEGF. The genetic sequences of their gene mentioned above are registered in public data bases and are easily cloned by a man of skill in related fields.
Blow is an example of gene of VGEF. “VEGF gene” in the present invention indicates the gene coding for VEGF protein and, in some case, simply designates the expression vector (?plasmid) encoding the VEGF gene. As concrete illustration a cDNA for VEGF is inserted into the virus vector mentioned after. Regarding human VEGF four subtypes (VEGF121, VEGF165, VEGF189, VEGF206) formed by alternative splicing in transcription of the human gene have been reported (Science, 219, 983, (1983); J. Clin. Invest., 84, 1470 (1989); Biochem. Biophys. Res. Commun., 161, 851 (1989)). Although it is possible in the present invention, that an either subtype of VEGF gene is used for constructing the expression vector, the gene for VEGF165 with the biologically strongest activity is preferable. In addition even the VEGF gene subjected to modifications are classified as the VGEF gene as far as they express the active protein with an angiogenesis activity.
The gene for VGF165 is easily cloned or modified by a man of skill in related fields according to information on the sequence registered in the literature (i.e. Science, 246, 1306 (1989)) or data bases.
The activity expressed by VEGF or its modified gene can be examined in vitro by their growth effect on vascular endotherial cells as described in WO97/07824.
Previously described gene for angiogenesis factors can be used singly or in combination with multiple gene.
Here, PGI2 produced by hPGIS shows the activities of vasodialation, accentuation of vasopermiability and anti-platelet aggregation and a combination of gene for PGIS and an angiogenesis factor brings a more remarkable combination effect.
On the other hand, in the present invention, as “a material with activity of vasodialation” is used PGI2 or preferably its analogs. Additionally, as a “material with activity of anti-platelet aggregation” is also used PGI2 or preferably its analogs.
In the present invention, “the material having activities of vasodialation and/or anti-platelet aggregation” is defined as the compound which produces PGI2 showing activities of vasodialation and/or anti-platelet aggregation, or enhances the production of PGI2. Properly it indicates the compound which enhances synthesis, production of induction of prostaglandin (I2?). Although the suitable compound can be any material including gene, proteins, low molecular weight chemicals etc., the gene for PGIS is utilized as the compound induces the enzyme synthesizing PGI2. The nucleotide sequence of the gene for PGIS are registered in public data bases and its gene is easily cloned by a man of skill in related fields.
Blow is an example of gene of human PGIS gene (hPGIS). In the present investigation “PGIS gene” indicates the gene coding for PGIS. Incidentally in some case PGIS gene constructed into an expression plasmid is also described as “PGIS gene”. Actually shown as an example is the clone obtained by inserting the PGIS cDNA recorded in B.B.R.C., Vol. 200, No. 3, p 1728-1734 (1994) and WO95/30013 into a proper expression vector. Furthermore, as well as in case of previously described VEGF, the expression constructs with modified PGIS gene are included in the PGIS gene as far as they are the gene coding for protein with the function of PGIS in the present investigation.
The present PGIS gene, as well as the VEGF gene, is also easily cloned on the basis of the sequence information described in the previously described reference and registered in public data bases by a man of skill in related fields and its modification of the clone is easily carried out. The expected activity of the protein coded by the present gene can be examined by assaying products, for example, using an enzyme immunoassay using 6-keto Prostaglandin Fla enzyme immunoassay kit (Cayman, Co., catalog #515211), or thin-layer chromatography detecting the products of prostacyclin synthase.
PGI2 as the compound with activities of vasodialation and/or anti-platelet aggregation or PGI2—inducing materials can be singly used or in combination of multiple compounds.
In relation to the present invention, the administration method, conditions and doses of drug composition of angiogenesis therapy are described below.
1) When used are PGI2 with activities of vasodialation and/or anti-platelet aggregation, and PGIS gene induces the production of PGI2, the gene coding for angiogenesis in use of gene for an angiogenesis factor described above, and the gene coding for angiogenesis in use of combination of gene for PGIS and an angiogenesis factor(s), namely in combination of two or more gene, i.e. the gene for PGIS and VEGF, they need to be in the form of drug for gene therapy.
When the present drug for angiogenesis is administered to a patient, an administration form with the virus vector is given as an example. Experimental manual books particularly describe the methods for preparation and administration of the drug (Separate Volume Jikken-igaku, Fundamental Technique for Gene Therapy (in Japanese), Yodosha Co, 1997; Separate Volume Jikken-igaku, Experimental Mehods for Gene Transfer and Expression Analyses (in Japanese), Yodosha Co, 1997; Handbook for R&D of Gene Therapy (in Japanese), ed. The Japan Society of Gene Therapy, NTS Co., 1999). Below the methods for preparation and administration of the drug are explained in detail.
By the way, in the present invention, the objective gene is inserted into the adeno-associated virus (AVV), and can be transfered into the target cells by infection of the recombinant virus (AVV) constructed by insertion of the gene into the adeno-associated virus (AVV) as a vector. Here, types 1, 2, 5, 8 of adeno-associated virus (AVV) are suitable, but types 1 or 2 are preferred.
In the present invention the vector is used for the purpose of transfer of the gene into the target region of the lesion. This selection of adeno-associated virus (AVV) as a vector is due to the efficient transfer of gene into non-dividing cells such as muscle, nerve and liver cells etc. and to the possible long-term expression maintained in these target cells.
Furthermore, the gene therapy drug in the present invention consisting of drug composition of angiogenesis is preferred to be type 1 or 2 of adeno-associated virus (AVV) with an efficient transfer activity of the gene into non-dividing cells such as muscle, nerve and liver cells etc.
Then as the transfer method of the gene-therapeutic drug to the patient, there are two methods: the in vivo method where the gene-therapeutic drug is directly delivered into the body; the ex vivo method where it is ex vivo transfected into a specified cells isolated from the human body and returned to the body (Nikkei Science (in Japanese), April issue, 1994, pp. 20-45; Gekkanyakuji (in Japanese), 36(1), 23-48, 1994; Separate Volume Jikken-igaku, 12(15), 1994; Handbook for R&D of Gene Therapy (in Japanese), ed. The Japan Society of Gene Therapy, NTS Co., 1999). The in vivo method is preferred in the present invention. When the drug for gene therapy is given to the patient, it is delivered in the pathway dependent on the disease as the therapeutic target and the target organ etc. For example the drug for gene therapy is injected into veins, arteries, hypodermic or intracutaneous tissues, and muscles, or directly given to the tissues with the lesion.
As the dose form, various types of dose forms, such as a liquid dose, suitable to their above mentioned administration form can be adoptable. For example, the injection as the dose form containing the active ingredient of a gene can be prepared by common methods. The injection is possibly prepared as follows: the ingredient, for example, is dissolved in a suitable solvent (a buffer such as PBS, saline, sterilized water etc) if necessary, subjected to mechanical sterilization by filtration, and filled in sterilized vessels. A commonly used carrier can be added to the injection. And in use of a liposome such as the HVJ-liposome, the injection can be a suspension, a frozen form or a frozen drug after centrifugal concentration.
And in order to an easy distribution of the gene around the site of the lesion the drug can be embedded around the lesion or slowly and continuously delivered with an osmotic pump.
Incidentally the content of the active pharmaceutical ingredient (API) of the gene can be adjusted according to the disease as the treatment aim, age of patient, body weight etc., is generally in a range of 0.001-100 mg, preferably 0.01-10 mg, which is suitably given to a patient once per days or months.
2) When used are PGI2 with activities of vasodialation and/or anti-platelet aggregation, and PGIS gene induces the production of PGI2, the gene coding for angiogenesis in use of gene for an angiogenesis factor described above, and the gene coding for angiogenesis in use of combination of gene for angiogenesis, and a low-molecular eight chemical, protein, peptide etc., they need to be in the form of drug for gene therapy. On the hand, low-molecular weight chemicals etc. in form of the general drug compositions are administered orally or parenterally. As a typical combination is considerably a combined use of VGEF gene and a PGI2 analog.
The above described drug compositions of low-molecular eight chemicals, proteins etc. as active ingredients are explained below.
When drugs with activities of vasodialation and/or anti-platelet aggregation (anti-platelet drug) are commercially available, their administration methods and dose can be determined according to their protocols. Generally, the dose form and administration method are as follows.
Namely, when the drug is orally administered, it is done in the dose form usually used in the specified field. When the drug is parenterally dispensed, it is administered as the dose form of a focal administration drug, an intrarectal administration drug, an injection, a nasogastric drug etc.
As the oral administration drug or focal administration drug, for example, the dose form of capsules, tablets, pills, powder, drop, suppository, liquid formulation etc. is conceived. For example, a sterilized solution, suspension, and emulsion etc, such as water, a water-propylene glycol mixed solution, a buffered solution, 0.4% saline etc. are conceived as the injection form. The dose form of cream, ointment, lotion, transdermal absorption agent etc. can be chosen as a focal administration drug.
The above dose forms are prepared to the formulations with pharmaceutically tolerably excipients and additives, by common methods employed in the pharmaceutical field. Pharmaceutically tolerably excipients and additives are carriers, binders, incenses, buffering agents, thickening agents, tinctions, stabilizers, emulsifiers, dispersing agents, suspensions, antiseptics, pH-adjusting agents, tonicity-adjusting agents infiltrate agents etc. In addition, pharmaceutically tolerably carriers for example, are magnesium carbonate, lactose, pectin, starch, methylcellulose etc.
When the previously described drug composition is given to the patient, it can be delivered in the pathway dependent on the disease as the therapeutic target and the target organ etc. For example it may be injected into veins, arteries, hypodermic or intracutaneous tissues, and muscles, or directly given to the tissues with the lesion. Additionally the drug composition is also possible to be administered orally or in its suppository form. Incidentally dose and administration frequency of the drug composition is depends on the symptom, age, body weight of a patient, and the administration form. Generally the dose per an adult is in a range of 0.001-100 mg a day, preferably 0.01-10 mg, which is suitably given to a patient once or multiple times divided.
The above mentioned drug compositions with a low-molecular weight chemical or protein as an active ingredient can be administered together with the gene-therapy drug containing the gene for angiogenesis, or separately at regular intervals.
The drug composition of angiogenesis therapy in the present investigation is described above. The present drug composition is useful if treatment or prevention of the peripheral arterial disease, which needs the angiogenesis therapy.
Below the present invention is concretely explained with a practice example, but the present invention is not restricted by this practice example.
The expression vector for human PGIS was constructed as described previously. In brief, the blunted HindIII/BamHI fragment of the full-length human PGIS cDNA was ligated into the blunted XhoI site of the pUC-CAGGS expression plasmid. To verify that the pUC/PGIS construct encoded a biologically active PGIS protein, pUC/PGIS was transfected into NIH3T3 cells, and conversion of [14C]-PGH2 to 6-keto-[14C]-PGF1α was measured. pUC-CAGGS vector lacking the insert served as the control vector. Human PGIS genes were then inserted into AAV-CAG plasmids, and AAV-hPGIS vectors were constructed. AAV-EGFP (enhanced green fluorescent protein) vector for control experiments was also prepared as described previously.
Eight-week-old male BALB/c nude mice (Japan CLEA) were anesthetized with diethyl ether, and the skin was incised over the femoral artery in the mid-portion of the left hind limb. The femoral artery was then gently isolated, and the proximal portion of the artery was ligated with 7-0 silk ligatures. All experimental procedures and protocols were reviewed and approved by the Animal Care and Use Committee of the Keio University School of Medicine, and they conformed to the NIH Guide for the Care and Use of Laboratory Animals.
Mice were divided into 3 groups (control, AAV-EGFP and AAV-hPGIS). The AAV-hPGIS group was administered AAV type 1-hPGIS (1.0×1011) into left thigh muscle. The control group was administered the vehicle (0.9% saline) into the left thigh muscle. As negative control, the AAV-EGFP group was administered AAV type 1-EGFP (1.0×1011) into same site. After 1 week of gene transfer, the left femoral artery of the mice was ligated to produce hind limb ischemia model. After 2 week of ligation, the incidence of limb necrosis was evaluated and blood perfusion rate of the mice was measured using Laser Doppler perfusion imaging (LDPI) system. The left thigh muscles were excised and utilitied for further analysis.
To examine the continuity of the expression of human PGIS mRNA , each 4 to 5 mice in the groups of hPGIS, control, and AAV-EGFP were administered AAV type 1-hPGIS (1.0×1011, v.g./body), into left thigh muscle of C57/BALB6 mice (8 week-old)
The three groups (AAV-hPGIS, CONTROL and AAV-EGFP) of mice are subjected to ischemia in left hind limbs, and the blood perfusion rate in the ischemic left (L) and normal right (R) hind limb was measured with a Laser Doppler perfusion imaging (LDPI) system (Moor LDI, Moor Instruments, USA). The measurement was carried out by taking LDPI of perfusion state of ischemic hind limbs in each group. The results are shown in
In
In
In
RNA extraction and quantitative RT-PCR were performed as described previously. Quantitative RT-PCR was performed with TaqMan probes (Applied Biosystems): human PGIS (Hs00168766_m1), mouse PGIS (Mm00447271_m1), mouse VEGF (Mm01281449_m1), FLK-1 (Mm01222419_m1), FLT-1 (Mm00438971_m1), and Rodent GAPDH. The mRNA levels were normalized by comparison to GAPDH mRNA. In
Membrane fractions of skeletal muscle were prepared by homogenization of thigh muscle in ice-cold buffer as described Immunodetection was performed on membrane extracts with an antibody to human PGIS. The results are shown in
Samples were fixed with 10% formalin, embedded with paraffin, and cut into 4-μm sections. The sections were stained with hematoxylin and eosin. In addition, thigh muscle sections were stained with anti-human PGIS antibody. The results are shown in
In
Animals were sacrificed under anesthesia, and perfusion fixation was performed with 4% paraformaldehyde. The thigh muscles were excised and embedded with OTC compound. Frozen sections (7 μm) were cut from the tissue specimens Immunofluorescent staining for endothelial cells was carried out with anti-von Willebrand factor (vWF) antibody (DAKO). Nuclei were stained with TOTO-3 (Molecular Probes). The density of microvessels was calculated from the number of vWF-positive vessels. All confocal microscopy was carried out on a LSM 510 META (Carl Zeiss, Jena, Germany). The capillary density was the ratio between the total area of capillary vessels and the total skeletal muscle area, each measured by Image J software. The data for each mouse were calculated from 30 serial sections.
All data are presented as the mean±SD. Statistical significance was evaluated using the unpaired Student t test. Comparisons among more than three groups were performed using analysis of variance. P<0.05 was considered significant.
Duration of hPGIS Expression After Administration of AAV Type 1-hPGIS Vector
By the present inventors etc. were examined the duration of expression efficiency by AAV type 1-hPGIS vector using 8-weeks control mice (C57/BL/6). Mice were administered AAV type 1-hPGIS vector into the left thigh muscle. For analysis the left thigh muscle from mice treated with before and after 2, 4, 8, 12 weeks vector administration. The results, as analyzed by quantitative RT-PCR, indicates a strong human PGIS mRNA expression from 2 weeks after gene transfer. The strong expression was maintained even after 12 weeks. The results are shown in Table 1.
Table 1 Change in expression of human PGIS after administration of AAV1-human PGIS vector (1.0×1011 (v.g./body)) into left thigh muscle
To treat limb ischemia model mice, the present inventor et al administered AAV type 1-hPGIS into left thigh muscle and examined the degree of improvement in the ischemia two weeks after the limb-ischemia operation. In examination the seriousness of limb ischemia was divided into three groups. As shown in
Using laser Doppler blood perfusion (LDP) the blood flow in limb muscle tissues of AAV-hPGIS, Control, and AAV-EGFP group mice was analyzed percutaneously. In the LDP images shown in
Analysis of mRNA in Ischemic Muscles
Expression of mRNA in ischemic limb tissues was analyzed using quantitative RT-PCR. Compared with Control and AAV-EGFP groups, a remarkably significant expression of human PGIS gene was observed in AAV-hPGIS group (see
Furthermore, gene expression at protein level was examined using western blot analysis. Western blots confirmed hPGIS protein in AAV-hPGIS administration group (see
Expression of hPGIS in Skeletal Muscles
Moreover, histological examination of the skeletal muscle of the region administered AAV-PGIS was carried out. Imunostaining with anti-human PGIS antibody confirmed expression of hPGIS gene/protein in muscle cells in AAV-hPGIS administration group (see
Additionally to examine improvement at the level of ischemic muscle cells, skeletal muscles were subjected to immunostaining with anti-vWF antibody. In confocal microscopy the increase in vEF-positive vessels was observed in AAV-hPGIS group compared with Control and AAV-EGFP groups, suggesting an increase in capillary density (see
The capillary density was expressed as the ratio between the total area of capillary vessels and the total skeletal muscle area. It was statistically significant that the density of vVW-positive microvessels in AAV-hPGIS group was 6.5 folds higher than that in Control and AAV-EGFP groups (see
As described above, neovascularization at the capillary level occurred in the ischemic skeletal muscles administered AAV-PGIS, suggesting reduction of ischemic injury of skeletal muscles.
It is shown from the facts described above that improvement of hind limb ischemia is obtained by transfer of human PGIS gene in ischemic skeletal muscles using AAV type 1 vector. Although many serotypes are known as AVV, AAV type 1 is known to have an ability of the strongest and long-term expression in skeletal muscles. It is reported by the present inventor et al that AAV type 1-human PGIS (AAV-hPGIS) shows a long-term strong gene transfer efficiency in the in vitro and in vivo control experiments. Additionally gene expression of AAV type 1 is limited in the local site of administration, and it is not found in remote organs. This characteristic of the expression can reduce the side effect of the gene therapy in remote organs, and is useful in the treatment of patients suffering from serious limb ischemia, which are complicated with arteriosclerosis-induced diseases in other organs.
As it is clear from previously described experimental results, the rate of necrosis in AAV-hPGIS group mice received an administration of AAV type 1-hPGIS, was significantly lowered and frequency of tertiary foot necrosis was lowest in AAV-hPGIS. Furthermore, in quantitative analysis by LDP the perfusion rate in AAV-hPGIS group caused a statistically significant increase compared with those in the two groups without administration of AAV-hPGIS. LDP image suggests that the development of collateral vessels contribute to the improvement of blood perfusion in ischemic limbs, because disruption of blood perfusion in femoral arteries by ligation, namely the blockage of femoral arteries was confirmed in all groups.
Subsequently, gene expression was examined with skeletal muscles, the administration site of AAV-hPGIS. The expression of PGIS gene was analyzed by quantitative RT-PCR. A remarkable gene expression of external human PGIS was observed with skeletal muscles in AAV-hPGIS group, and was ten thousand-folds compared with those of the control groups. An enhanced two-fold gene expression of intrinsic VEGF was also observed with skeletal muscles in AAV-hPGIS group, suggesting induction of VEGF by expression of external human PGIS. Using immunostaining of hPGIS a remarkable expression of human PGIS protein was observed in skeletal cells mediated AAV-hPGIS. In addition, any inflammatory changes and tumor formation of muscles was not found by the AAV viral administration. The findings prove the safety of AAV-PGIS, and coincide with the fact that AAV has the lowest immunogenicity among virus vectors.
Furthermore, by the present inventors skeletal muscles was subjected to immnostaining with anti-vWF antibody in order to examine whether neovascularization occurs or not. In AAV-PGIS group neovascularization was confirmed at the capillary level. Incidentally EVG-staining for elastic fibers in skeletal muscles was carried out and significant changes were not observed in all treated groups, suggesting that the neovascularization at capillary level occurs in skeletal muscles administered AAV-hPGIS.
It is demonstrated from results mentioned above that transfer of AAV-hPGIS into skeletal muscles improves limb ischemia by a remarkable expression of human PGIS in skeletal muscle cells, leading to production in the muscle cells and secretion of PGI2 meditated by the expression, which induces activities of vessel protection, induction of neovascularization etc. And it is noteworthy that the effects mentioned above were achieved by single administration. Previous clinical and basic research reports reveal that the strong continuous gene expression could not be maintained due to plasmids, non-viral vectors etc. without a property of long-term expression. Thus, with use of these vectors the multiple-time administration is neccesary to keep the gene expression. The highly safe virus vectors such as the AAV vector achieving a long-term and strong expression can be ideal for clinical applications
| Number | Date | Country | Kind |
|---|---|---|---|
| 2009-200900 | Aug 2009 | JP | national |
This is a continuation of U.S. patent application Ser. No. 15/404,076 filed on Jan. 11, 2017, now pending, which is a continuation of U.S. patent application Ser. No. 13/393,062 filed on Feb. 28, 2012, now pending, which is a nationalization of PCT/JP2010/005321 filed on Aug. 30, 2010. This is also a continuation of U.S. patent application Ser. No. 13/393,062 filed on Feb. 28, 2012, now pending, which is a nationalization of PCT/JP2010/005321 filed on Aug. 30, 2010. This application claims the Paris Convention priority based on Japanese Patent Application No. 2009-200900 filed on Aug. 31, 2009. The contents of these applications, including the specifications, the claims and the drawings, are incorporated herein by reference in their entirety.
| Number | Date | Country | |
|---|---|---|---|
| Parent | 15404076 | Jan 2017 | US |
| Child | 16373388 | US | |
| Parent | 13393062 | Feb 2012 | US |
| Child | 15404076 | US | |
| Parent | 13393062 | Feb 2012 | US |
| Child | 13393062 | US |
